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Zoonoses include a broad range of diseases, that are becoming of great interest, due to the climate changing, that cause the
adaptation of vectors to new niches and environments. Host immune responses play a crucial role in determining the outcome
of infections, as documented by expansion of antigen-specific T cells during several zoonotic infections. Thus, understanding
of the contribution of antigen-specific T-cell subsets in the host immune response is a powerful tool to evaluate the diﬀerent
immunological mechanisms involved in zoonotic infections and for the development of eﬀective vaccines. In this paper we discuss
the role of T cells in some eukaryotic and prokaryotic infectious models.
1. Introduction
Zoonotic diseases are a significant burden on global econ-
omies and public health [1] and are due to the unaware
role of wild and domestic animals, which act as reservoir or
hosts of the etiological agents. More than 60% of emerging
infectious diseases are constituted by zoonoses and the
majority of these are increasing significantly over time [2].
In 2009 the World Organization for Animal Health (OIE)
has commissioned Civic Consulting to conduct a study on
the Cost of National Prevention Systems for Animal Diseases
and Zoonoses, estimating that in developing and transition
countries substantial diﬀerences in the public expenditure
for the National Prevention System for Animal Diseases
and Zoonoses exist, reaching from 10 million international
dollars to 167 million international dollars [3]. The impair
they cause should be attributed not only to human and
animal suﬀering but also to the hampering agricultural
production, the decreasing of food availability, and the
creation of barriers to international trade [1], as well as the
veterinary management, the maintenance of surveillance
plans, and the capillary control in the food industry chain of
production.
Many zoonotic agents are transmitted by vectors, others
by contaminated water or food, and others by direct trans-
mission. A broad range of pathogens can be responsible for
zoonoses, ranging from virus to prokaryotic to eukaryotic
(unicellular or multicellular), and the great diﬀerence in the
antigenic input for the immune system of the hosts implies
that many diﬀerent branches of immunity could be involved
in protection or pathogenesis.
T cells play a pivotal role in immune functions since they
are able to act not only diﬀerentiating in diﬀerent subsets
(including γδ T-lymphocytes and Cytotoxic T-Lymphocytes)
but also inducing the production of antibodies that inhibit
the pathogen spreading, both directly and with the help of
other branch of the immune system.
Homeostatic cytokines are those factors able to regulate
multiplication and diﬀerentiation of many cell types; T
cells are dependent on contact with IL-2, IL-7, and IL-15,
for their survival and intermittent homeostatic proliferation
[4]. T-helper cell diﬀerentiation is instructed by distinct
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environmental cytokines, that upregulate the expression of
lineage-specific transcription factors and inhibit the alternate
diﬀerentiation pathways [5]. The contact between the naı¨ve
T cell and the antigen induces the expression of IL-2 and
IL-2 receptor leading to the entry of the T cell into several
rounds of proliferation and to the diﬀerentiation in Th1,
Th2, Th17, and induced regulatory T (iTreg) cells. The
process consist of an intriguing cytokines puzzle, where IL-
4 plays a major positive feedback role in Th2 diﬀerentiation,
and IFN-γ, together with IL12, determines Th1 induction
[6]. IL6 and IL1 are necessary for Th17 production, while
the role of TGFβ needs still to be deeper investigated [7, 8].
Finally, activated naı¨ve CD4 T cells stimulated by TGF-β in
the absence of proinflammatory cytokines develop into iTreg
cells [9].
The complex network of cytokines function is resolved
in a balance from diﬀerent T-cell activation pathways
(Th1/Th2, Th1/Treg, Th2/Treg, Th1/NK, and/or γδ T
cells). Although T-cell-mediated immune response during
zoonotic infections is poorly studied, the facilities in the
setting-up experimental conditions make it good system
for a deeper investigation on the specific activation of T-
lymphocytes.
It is well known that protozoan, helminthic parasites, and
intracellular bacteria are able to survive within the host, in
spite of the activation of both innate and adaptive immune
response [10]. Zoonotic infections caused by eukaryotic
organisms are intriguing systems where the antigen-specific
T-cell expansion can be studied [11].
Helminthes have the ability to drive the diﬀerentiation of
naı¨ve CD4 T cells to the Th-2 subset of eﬀector cells which are
able to eliminate the pathogens by the actions of antibodies
induced by Th2 cytokines. During a protozoarian infec-
tion, protozoa are usually phagocytosed into macrophages,
previously activated by Th1 lymphocytes, and are able to
survive evading host immune response. As it happens in the
case of intracellular bacteria, infected cells loose the ability
to kill the pathogen, and Cytotoxic T-Lymphocyte- (CTL-)
mediated immune response is needed for the elimination
of microorganisms into macrophages [12] (Figure 1). The
naı¨ve T cells encounter the antigen in the peripheral lymph
node, develop toward eﬀector cells, and migrate to the site of
infection for the killing of infected cells. This process is finely
tuned by cytokines cross-talk and microbial ability to evade
host immune response.
B cells and humoral response play the main role in the
clearance of extracellular bacteria. Nevertheless, a certain
enrolment of T-cells has been demonstrated [13]. In this
paper, we draw attention on diﬀerent mechanisms of T-cell-
mediated immunity, in order to compare the mechanisms of
immune modulation induced by various zoonotic agents.
2. T Cells and Cytokines Induced by
Eukaryotic Zoonotic Agents
The nematode parasites Toxocara (T.) canis and T. cati
choose dogs and cats as definitive hosts, respectively. Some-
times, when embryonated eggs are accidentally ingested
by humans, larvae hatche in the small intestine, penetrate
the intestinal wall, and cause the larva migrans syndrome
[14]. Toxocariasis symptoms are classified according to the
organs aﬀected in visceral larva migrans (VLMs) and ocular
larva migrans (OLMs). In the latter toxocariasis pathological
eﬀects on the host are restricted to the eye and optical nerve
[15], while in the case of VLM, symptoms can persist for
more than one year and include abdominal pain, coughing,
headache, and normal or mildly elevated eosinophilia [16]. A
recent survey [17] emphasizes that the seroprevalence value
among humans is considerably high, thus demonstrating
the relevance of this pathology. T. canis is able to control
host immune response, through the modulation of cytokines
produced by immune cells. The immunomodulatory eﬀect
has been demonstrated in mice, where the stimulation of
normal macrophages with T. canis antigen in vitro induced
IL-1α, IL-6, IL-10, and TGF-β, but not IL-12 and TNF-α
[18]. Prototypical immune responses are characterized by
increased lymphoproliferation of CD4+ and CD8+ T cells,
increased production of IL-4 and IL-5, eosinophilia, and
augmented production of IgE, as previously described in
humans and mice [13–15]. As regards the immune response
in dogs, it has been demonstrated that T. canis is able to
induce antigen-specific IFN-γ production in pregnant dogs
and in their puppies [19]. Blood mononuclear cells (BMCs)
were isolated from pregnant dogs and their puppies and
were cultured in the presence of ESAg (Excretory/Secretory
Antigen of T. canis). Cytokine levels were tested in cultures’
supernatants by ELISA, and it was noted that IL-10 concen-
tration increases during pregnancy in infected animals while
IFN-γ production decreases. On the contrary IL-10 concen-
tration decreases with the age of infected puppies while IFN-
γ amount increases. It appears clear that immune cells of
infected dogs undergo T. canis-induced modifications. These
modified pattern of cytokines detected in T. canis could
be due to a synergistic eﬀects of physiological changes of
immunity during pregnancy and in the first month of life,
and/or direct eﬀects mediated by parasite interaction with
host immunity. The finding that IL-10 and IFN-γ levels were
significantly modified in infected pregnant dogs and their
puppies provides new perspectives for immunotherapeutic
interventions based on switch of Th2 to Th1 cytokine pattern
in females before pregnancy.
Another system to understand the role of T cells in
eukaryotic zoonotic infections is echinococcosis. Alveo-
lar echinococcosis is caused by the metacestode stage of
Echinococcus multilocularis. The definitive hosts are the
foxes, which release Echinococcus eggs in the foecal matter,
spreading them in the environment. Little rodents acquire
the infection by ingesting eggs and carry the infection in
their liver. Humans are aberrant intermediate hosts [20].
In humans, metacestode stage of the worm aﬀects the liver,
where an abdominal mass develops; other symptoms may
arise like abdominal pain, jaundice, and liver failure [21].
The severity of the disease is dependent on the genetic
background of the host and on the balance between the
Th1-related immune response, associated with protection,
and the induction of the immune tolerance by the parasite
itself [22]. In experimentally infected C57BL/6J mice the
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Figure 1: Schematic network of cells and molecules in response to zoonotic agents. An “oversimplified” scenario constituted by various
cells and molecules involved both in binding of epitopes derived from pathogens and in the eﬀector mechanisms hereby represented. APCs
bind zoonotic derived epitopes and present them to various types of lymphocytes, in the context of MHC molecules and/or Toll-Like
Receptors (TLRs). These subsets, producing diﬀerent cytokines, could activate eﬀector “protective” mechanisms involving macrophage
killing, cytotoxic activity by CTL and/or CD4, and release of various cytokines, thus leading to the damaging of zoonotic pathogens.
The killing by CTL, that could be not only CD8 but also NK cells, could be also due to an ADCC phenomenon with the contribution
of antizoonotic epitopes,-specific antibodies.
promotion of the disease seems to be associated with the
expansion of diﬀerent T-cell subsets: spleen cells harvested at
diﬀerent time points after infection were stimulated in vitro
with a crude parasite extract. A strong CD4+ proliferative T-
cell response was observed at the early stage of infection, and
IFN-γ, IL-2, and IL-5 were produced within the first weeks
after infection whereas the detection of IL-10 was slightly
delayed [23]. Cystic echinococcosis is caused by E. granu-
losus. The main domestic cycle is maintained between dogs
and sheep, with man as accidental intermediate host. The
disease is acquired by ingesting eggs, originating from the
faeces of definitive hosts (dogs, wolves, and other carnivores)
[24], and it typically aﬀect, the liver. It is often asymptomatic,
but in case of rupture of the cyst, secondary infection
and anaphylactic reaction can occur. The most frequent
complications are pain, obstructive jaundice, cholangitis and
sometimes shock [25]. It has been demonstrated that a
restimulation of PBMC from aﬀected patients with the crude
antigen induces an upregulation of IL-5 and IL-10 [26] as
well as a downregulation of IL-1 and TNF-α mRNAs [27].
The opportunistic parasite Toxoplasma gondii belongs
to the phylum apicomplexa. Feline acts as definitive hosts
in its life cycle, while mammalians, including humans,
are intermediate hosts. Human toxoplasmosis is usually
asymptomatic or paucisymptomatic, but the parasite is able
to cross the intestinal barrier and disseminate through the
body, reaching muscle, central nervous tissues, eyes, and
placenta [28]. Congenital toxoplasmosis may hesitate in
retinochoroiditis and/or mental abnormalities [29].
The infection by T. gondii induces a strong cellular
response essential for the host resistance [30]. In particular,
it has been noted since 1990 that upon an in vitro stimulation
with T. gondii antigen, a strong CD8+ T-cells response,
sustained also by CD4+cells expansion, is mounted [31].
The role of CD4+ in the activation of CD8+ has been
demonstrated in mice [32], where the generation of optimal
numbers of antigen specific CD8+ eﬀector T cells was found
to require CD4+ T-cells help. The parasite is also able to
induce a strong natural killer (NK) cells activation and
macrophages production of IL-12, both ending in a massive
IFN-γ production. The IFN-γ production is sustained by
γδ-T lymphocytes [33] that help CD4+ and CD8+T cells to
restrict parasite growth until the emerging of the complete
adaptive response. It has been recently demonstrated that
the CD8+ T-cells response is sustained both by “homeostatic
cytokines” IL-15 and IL-7 and that the absence of IL-15 or
IL-7 alone does not aﬀect CD8+ T cell activation during acute
toxoplasmosis [34], thus suggesting that these cytokines
could act in synergy. Immune response of congenitally
infected newborns to T. gondii undergoes to a process that
leads to anergy [35, 36], probably due to a developing
immune system of the infant. In this case, both αβ- and γδ-T
cells become unresponsive when stimulated with T. gondii-
specific antigen. Nevertheless, Vδ2+ γδ T cells are able to
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lose tolerance before αβ-T-cells, and to confer protection
against the chronic phase of infection in congenitally infected
children [37]. Indeed, γδ T cells are considered to undergo
peripheral tolerance, thus persisting in blood longer than αβ
T lymphocytes which are deleted in the thymus during T.
gondii infection [37].
A useful model to better understand immune response
to eukaryotic zoonotic agents is constituted by Leishmaniasis
and its related immunity. Leishmaniasis is a vector-borne dis-
ease caused by obligate intramacrophage protozoan parasite
of the genus Leishmania and its incidence is increasing in
nonendemic areas due to changing patterns of international
travel and to population migration [38]. Visceral leishma-
niasis (VL) or kala-azar is one of several diseases caused by
more than 20 species of the protozoan parasite Leishmania.
The infection tends to aﬀect mainly children, but immuno-
suppression and HIV increase the possibility to contract the
illness. The common symptoms are fever, malaise, shivering
or chills, weight loss, anorexia, and discomfort in the left
hypochondrium [39]. In experimental L. major infections
genetically resistant mice develop a T-cell response domi-
nated by a CD4+ (Th1) phenotype characterized by IFN-γ
secretion while in susceptible mice the dominant response
is a CD4+ (Th2) phenotype characterized by interleukin
IL-4, IL-5, and IL-13 secretion [40]. These observations of L.
major in mice led to the emergence of the Th1/Th2 paradigm
as opposing cytokine responses in the control of infections
[41, 42]. The balance of Th1 to Th2 responses determines the
outcome to infection. In the natural disease both Th1 and
Th2 cellular subtypes are activated. Resistance to infection
depends on production of cytokines such as IFN-γ, TNF,
IL-2, and IL-12. These cytokines stimulate cell-mediated
immunity which eliminates the infection activating leish-
manicidal activity of macrophages [41, 42]. The infection
in dogs shows diﬀerent clinical presentations, from subclini-
cal/asymptomatic to a fully developed disease, depending on
the host’s immune responses. The Th1/Th2 dichotomy is not
clear in the diﬀerent forms of canine leishmaniases, because
it depends on physiological status of the infected subject.
The production of IL-4, IL-5, IL-6, and IL-10, which in turn
promote B-cell proliferation and antibody production, is the
cause of susceptibility of dogs, which become not able to
control the infection [43–45]. Our experience is focused to
evaluate cytokine expression level with a quantitative real-
time PCR assay to measure expression levels of cytokines
relative to either Th1 or Th2 patterns in the blood of nat-
urally infected asymptomatic dogs. High expression levels of
IL-2 and IFN-γ were detected at the first observation, which
decreased over time. Opposite cytokine-based eﬀects were
detected in infected dogs. In those that had a clinically evi-
dent outcome, IL-2 and IFN-γ were initially not expressed,
but their levels suddenly increased with the appearance of
clinical signs [43]. Furthermore from our study it was con-
firmed that IL-12 represents a marker of active disease, while
IL-18 cannot be involved in the progression from asymp-
tomatic to active disease. These data suggest that response
to Leishmania in the dog does not fit into a specific cytokine
profile.
3. Antigen-Specific T Cells and
Derived Cytokines Detection in
Prokaryotic Infections
Among prokaryotic microorganisms able to cause zoonotic
disease, Leptospira, Brucella, and Mycobacteria oﬀer suitable
models to analyze the role of immune response against these
pathogen since the related immunity could involve diﬀerent
antigen-specific T cell subsets. Leptospira interrogans is one
of the main causative agents of leptospirosis. The pathogen is
able to persist in the kidneys of infected (wild and domestic)
animals and is spread in the environment through their
urine. It is transmitted to humans through skin abrasions
and causes haemorrhage, diarrhoea, renal impairment, and
aseptic meningitis [46]. Phagocytosis is the main process
that allows the clearance of the pathogen, and it has been
recently demonstrated that the bacteria undergo a complex
transcriptional regulation in order to evade host immune
response [47]. In particular they downregulate the major
OMPs (Outer Membrane Proteins) through the action of a
hypothetical transcriptional factor. It is well accepted that
humoral immunity has an important role for the elimination
of extracellular bacteria, but sometimes antibodies alone
could not be suﬃcient, especially in the case of L. borg-
petersenii serovar Hardjo [48]. In this and other cases, IFN-
γ plays an important role for the activation of macrophages
and the production of IgG2 class of immunoglobulins [49,
50]. The involvement of a cellular immune response has been
recently demonstrated: a strong Th1 response was recorded
by the observation of the IFN-γ production following the
in vitro stimulation of vaccinated bovine PBMC with the
specific antigen [51]. The results from vaccinated animals
indicated that approximately two-thirds of IFN-γ+ cells were
within the CD4+ T-cell population while the remaining one-
third were γδ T cells [51]. Furthermore, Guo et al. have
recently reported the existence of specific cytotoxic CD8+
T cells in patients with leptospirosis and have detected a
potential epitope of the leptospiral protein LigA, able to
elicit specific cytotoxic T-lymphocyte (CTL) responses [13].
Naiman and Guo suggest that Th1 response to Leptospira
requires the cooperation between two or more T cell subsets
like γδ, CD8+, CD4+, and so forth. In Leptospira-infected
hamsters a new soluble factor was shown to be important
for the protection: IP-10 [52]. This evidence points to T
cell-derived chemokines in zoonosis. These proteins are able
to induce cell migration from lymphoid organs to aﬀected
tissues and they are also considered markers of T cell matu-
ration [53]. Indeed, future approaches for a deeper analysis
of T cell response in zoonoses could be comprehensive of
the characterization of the released chemokines and their
receptors.
A very hot field in veterinary immunology is represented
by T cell responses against intracellular bacteria. Tuberculosis
and Brucellosis remain major worldwide health emergencies
among zoonotic bacterial infections, and a better under-
standing of the host immunological reactions to these
pathogens is fundamental for improving both therapies and
vaccines strategy, as well as to prevent dissemination of the
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infectious agents in the herds. Tuberculosis causes in host
mild fever and a wide range of symptoms depending on
the localization of the Mycobacterium (pneumonia, kidney
failure, meningitis especially in children, etc.) [54].
Animal tuberculosis is mainly observed in cattle (less
frequently also in horses, swine, dogs, cats, sheep, and
goats), caused by Mycobacterium (M.) bovis, and in birds,
due to M. avium. Human tuberculosis is mainly caused
by M. tuberculosis, but around 10% of total infections are
due to M. bovis, typically as professional disease, while M.
avium can cause disease in immunodeficient patients [55].
Dogs and parrots are highly susceptible to M. tuberculosis
by the contact with infected humans. T-lymphocytes play
a central role in the control of M. tuberculosis replication,
as this infection evokes a strong cell-mediated immune
response. Protective immunity against M. tuberculosis is
due to adaptive cellular immune responses, and protective
immunity correlates to the induction of T cell cytokines
following antigen specific stimulation. CD4+ and CD8+ T
cells are key components of anti-mycobacterial immunity
[56, 57]. Both IFN-γ production and cytotoxic activity
against infected target cells contribute to bacteria killing with
lysis of infected cells [58, 59].
T cells response after in vitro stimulation of human
PBMCs with M. tuberculosis-specific antigens (e.g., Purified
Protein Derivative, or PPD) can be assessed by measuring
intra- and extracellular IFN-γ [60]. The severity of M.
tuberculosis infection may be detected by measuring CD4+
and CD8+ T cells, as their numbers markedly decrease
in patients with severe tuberculosis, which can be a sign
of suppressed cellular immunity in these patients [60].
Particularly, patients with active TB have a lower number
of both CD4+ T cells and their naı¨ve, eﬀector, and late
diﬀerentiated memory subsets [61], with a drop in all
the three phenotypic populations. Similarly, CD8+ T cells
counts were also significantly diﬀerent between infected
and negative patients. At least partially, these disturbances
seem to be restored to baseline after successful therapies
[61].
In our experience with cattle [62] it has been showed
that cocktails of epitopes from ESAT-6 (the 6 kDa early
secretory antigenic target of Mycobacterium tuberculosis) are
recognized with high frequency by CD8+ T lymphocytes of
naturally infected cattle, thus confirming a role of ESAT-
6 specific CD8+ T cells in the response to M. bovis.
Nevertheless, the number of IFN-γ-positive CD8-negative
cells was larger than that of IFN-γ+ CD8+ T cells, indicating
that IFN-γ+ CD8+ T cells are not the dominant subset
responding to stimulation with ESAT-6-derived peptides.
Nevertheless, ESAT-6-specific T-cell expansion could be
useful to detect the early phase of the disease thus limiting
the dissemination of M. bovis.
Other cytokines such as TNF-α, IL-2 [63], MCP-2 [64],
and IP10 [65] were shown to be involved in the anti-
mycobacterial immune responses in humans; Th1- and
other cytokines interacting with macrophages are commonly
considered as mediators of anti-mycobacterial biological
agents. When reagents for the detection of these cytokines
in vertebrates will be available, it could be intriguing to
understand the role of these cytokines in mycobacterial
immune response also in veterinary infections.
Brucellosis is a multisystemic disease with a broad range
of symptoms, usually beginning with acute febrile illness,
headache, malaise, and myalgia. Gastrointestinal signs as
vomiting, anorexia, and nauseamay also occur [66]. Humans
are susceptible to Brucella (B.) suis, B. Abortus, and B.
canis, and, more frequently, to B. melitensis. The disease
can be transmitted by both direct and indirect contact with
infected animals or secretions, or by eating contaminated
food (especially unpasteurized milk and fresh cheeses).
Interhuman transmission is extremely rare [67].
Brucella invades and proliferates within monocytes. In
addition to the central role of monocytes/macrophages,
other cells of the innate immune response are recruited
and influence the interaction between bacteria and host.
For instance, human Vγ9Vδ2 T cells play an important role
in the early response to infection [67], and their number
dramatically increases in the peripheral blood of patients
with acute brucellosis [68], reaching 30% of the total T
lymphocytes. Vγ9Vδ2 T cells are specifically stimulated by
Brucella to secrete TNF-α, important for the autocrine acti-
vation of macrophage functions, IFN-γ, and other cytokines
[69]. In vitro, Vγ9Vδ2 T cells exhibit a strong cytotoxicity
against Brucella-infected cells. Vγ9Vδ2 T cells decrease the
development of intracellular Brucella releasing lytic granules
and/or acting through Fas-mediated signals to lyse infected
macrophages. It was also shown that the recruitment of
NKG2D by its ligands is suﬃcient to induce cytokine pro-
duction and the release of lytic granules thus increasing the
TCR-triggered responses of Vγ9Vδ2 T cells. The interaction
between NKG2D and its main ligand expressed on Brucella-
infected macrophages, UL16-binding protein 1 (ULBP1), is
involved in the inhibition of bacterium development [69]. As
demonstrated in the case of Vγ9Vδ2 T cells, it was shown that
also NKT cells are able to exert an anti-Brucella in vitro activ-
ity, either secreting cytokines or killing infected macrophages
[70]. NKT and Vγ9Vδ2 are considered as quite unrestricted
T cells as they do not recognize MHC and peptides, but
they expand following stimulation with nonpolymorphic
MHC-like molecules CD1 and/or with nonpeptidic and
glycolipid ligands. A cross-talk between Vγ9Vδ2 and NKT,
due to cytokines released in the milieu, could be responsible
for the activation of NKT in synergy with a possible
upregulating role of CD1 molecules expression exerted by
Brucella antigens. The previously described subsets activated
during Brucella infection could exert a protective role during
Brucella infection through their potent cytotoxic activity.
4. Concluding Remarks
Each microorganism hereby evaluated elicits a particular
type of immune response. A “classical” Th1-mediated
protective immune response was detected during zoonotic
infections like leishmaniasis or tuberculosis. Toxoplasma-,
Brucella- and Leptospira-induced immune response involves
a wide range of T cells including γδ and NKT cells. The in
vitro and ex vivo detection of T cells upon stimulation with
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the specific antigen allows going insight in the host/pathogen
interaction. The equilibrium established after such dialogue
is critical for the further ongoing of the infection. A
complex network of T cells, cytokines, and chemokines could
be studied to better understand the interactions between
zoonotic agents and receptors of innate and adaptive immu-
nity. This tool could be useful to develop vaccines and
immunotherapies in the next future.
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